|Day Low/High||37.48 / 38.62|
|52 Wk Low/High||24.54 / 39.44|
Straying from these names could land you in quicksand as the 4th quarter begins.
First peripheral vascular interventional technology approved in the U.S. to offer sustained release of antiproliferative drug to treat patients with peripheral artery disease
First head-to-head trial assesses effectiveness of sustained drug release in interventional treatment for patients with blockages in femoropopliteal arteries
New Data at World Congress of Endourology Demonstrate the LithoVue Empower Device Improves OR Experience
For most of this year the market has been led by growth stocks.
MARLBOROUGH, Mass., Sept.
Analyst downgrades and mind-boggling P/E ratios do not matter in this current market.
The Healthcare sector has seen a revitalization year-to-date, and these investors may have wanted to participate in a continued move higher, risking a fraction of the price of a share in the event they were 'late to the party.'
Acquisition expands portfolio of men's health in-office procedures with adjunctive therapy for prostate cancer patients
MARLBOROUGH, Mass., Sept.
MARLBOROUGH, Mass., Aug.
Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.
It is all about perception, and here are strong names to pick up on market weakness.
Acquisition to Bolster Company's Venous Therapies Portfolio within Peripheral Interventions Division
CMS Grants NTAP Designation for The Sentinel® Cerebral Protection System
MARLBOROUGH, Mass., July 30, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 38 th Annual Canaccord Genuity Growth Conference on Wednesday, August 8, 2018 in Boston.
MARLBOROUGH, Mass., July 25, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.
MARLBOROUGH, Mass., July 24, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation (TRC) to purchase up to three million shares of Boston Scientific's common...
Addition of FDA-cleared Sentinel® Cerebral Embolic Protection System to Expand Company's Structural Heart Offerings
Company to expand atrial fibrillation ablation therapy offerings with innovative cryoballoon platform
MARLBOROUGH, Mass., July 2, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2018 on Wednesday, July 25, 2018 at 8:00...
The heart-implant manufacturer is down some 4% over two days, but is up 128% year to date.
Jim Cramer takes a closer look at Magellan Midstream Partners, Xylem, Boston Scientific, Karyopharm Thereapeutics, Iovance Biotherapeutics, Casella Waste Systems and more.
Jim Cramer says higher rates always trigger rotations. Here's what investors should expect.
Jim Cramer and our other experts discuss the AT&T/Time Warner ruling, Alzheimer plays, and day traders risk.
The medical device firm issues an 8-K filing on the heels of a media report earlier this week that said it recently made a takeover approach to Boston Scientific.
Stocks closed higher on Monday as Wall Street prepares for an extraordinary week for risk events around the world.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.